US2013064913A1PendingUtilityA1

Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes

Assignee: TRIPP MATTHEW LPriority: Jun 20, 2001Filed: Jun 1, 2012Published: Mar 14, 2013
Est. expiryJun 20, 2021(expired)· nominal 20-yr term from priority
A61K 36/23A61K 36/73A61P 3/00A61K 36/282A61K 36/48A61K 36/80A61K 36/31A61K 36/3486
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.

Claims

exact text as granted — not AI-modified
1 - 5 . (canceled) 
     
     
         6 . A method for adipocyte modification for the treatment of insulin related disorders in a subject in need thereof, said method comprising administering to the subject a composition comprising a therapeutically effective amount of a pharmaceutically acceptable botanical product, wherein the botanical product is a compound or extract derived from acacia or hops, wherein
 a. wherein the acacia derived botanical product is derived from  Acacia catechu  or  Acacia nilotica ; and   b. wherein the botanical product derived from hops is selected from the group consisting of prenylflavonoids, chalcones, reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, xanthohumol, isoxanthohumol, 6-prenylnaringen, and 8-prenylnaringenin.   
     
     
         7 . A composition for adipocyte modification for the treatment of insulin related disorders in a subject in need thereof, said composition comprising a therapeutically effective amount of a pharmaceutically acceptable botanical product, wherein the botanical product is a compound or extract derived from acacia or hops, wherein
 a. wherein the acacia derived botanical product is derived from  Acacia catechu  or  Acacia nilotica ; and   b. wherein the botanical product derived from hops is selected from the group consisting of prenylflavonoids, chalcones, reduced isoalpha acids, dihydro-isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, xanthohumol, isoxanthohumol, 6-prenylnaringen, and 8-prenylnaringenin.

Join the waitlist — get patent alerts

Track US2013064913A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.